首页> Annals of lymphoma> Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort.

Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort.

导出 LinkOut

翻译打印收藏纠错

第一作者： Prakirthi,Yerram

第一单位： Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

作者： Prakirthi,Yerram ^[1] ; Samantha N,Reiss ^[1] ; Lisa,Modelevsky ^[1] ; Lauren,Schaff ^[2] ; Anne S,Reiner ^[3] ; Katherine S,Panageas ^[3] ; Christian,Grommes ^[2]

作者单位： Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[1] Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[2] Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[3]

关键词 Primary central nervous system lymphoma (PCNSL)methotrexate rituximab standard of care survival

DOI 10.21037/aol-22-19

PMID 37067886

发布时间 2023-04-18

基金项目

P30 CA008748/CA/NCI NIH HHS/United States

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Annals of lymphoma

2023年7卷

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Annals of lymphoma

2023年7卷

检索历史清除

Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort.

Annals of lymphoma

相似文献

同项目论文

Annals of lymphoma

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort.

Annals of lymphoma

相似文献

同项目论文

Annals of lymphoma

相关期刊

检索历史清除